Reuters - Lilly Alzheimer's Drug An Unlikely Ace In The Hole

 – February 2, 2012  –– 

A treatment for Alzheimer's disease is the drug industry's longest shot, and any brave investors willing to place a bet on the outcome are likely to focus on Eli Lilly & Co. Lilly and Pfizer Inc. are the farthest along in developing experimental medicines for the memory-robbing disease. But Lilly, as the far smaller company, has much more upside for its share price if it hits pay dirt. Dr. Sam Gandy, associate director of the Alzheimer’s Disease Research Center at Mount Sinai School of Medicine, said brain scans and new imaging agents in the past few years have enabled doctors to detect plaque long before symptoms of Alzheimer's develop. "The demand for new evaluations is already skyrocketing," Dr. Gandy said.
- Dr. Sam Gandy, Professor, Neurology, Psychiatry, Associate Director of the Mount Sinai Alzheimer's Disease Research Center, Mount Sinai School of Medicine
Learn more: http://www.reuters.com/article/2012/02/01/us-lilly-alzheimers-idUSTRE8102QS20120201